Document Detail

Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence.
MedLine Citation:
PMID:  18404369     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Promoter methylation of tumor suppressor genes in histologically negative sentinel lymph nodes (HNSN) of early stage breast cancer patients has not been extensively studied. This study evaluates the methylation frequency and pattern in HNSN to determine if detection of hypermethylation of one or more genes is associated with an increased recurrence risk in node negative breast cancer.
EXPERIMENTAL DESIGN: In 1998, a prospective study of patients with early stage breast cancer and HNSN was initiated in order to correlate sentinel node analysis with clinical outcome. Nodal tissue was selected from 120 HNSN patients for methylation analysis in at least one and up to six sentinel nodes using a panel of nine genes. Corresponding primary breast tumors from 79 patients were also evaluated for hypermethylation. Methylation analysis was performed using nested Methylation Sensitive PCR (n-MSP). Logistical regression was used to evaluate the relationship between clinical recurrence and methylation status.
RESULTS: Over a median follow-up of 79 months, 13 of the 120 patients had clinical recurrence. Hypermethylation of genes was frequently observed in HNSN, but there was no correlation of methylation pattern and clinical recurrence. However, increased frequency of gene methylation of the primary tumor correlated with clinical recurrence.
CONCLUSIONS: Although hypermethylation of multiple genes occurs frequently in HNSN of breast cancer patients, it is not associated with breast cancer recurrence in the first 7 years of clinical follow-up.
Hetty E Carraway; Shelun Wang; Amanda Blackford; Mingzho Guo; Penny Powers; Stacie Jeter; Nancy E Davidson; Pedram Argani; Kyle Terrell; James G Herman; Julie R Lange
Related Documents :
15154009 - Three independent genetic profiles based on mucin expression in early differentiated-ty...
14657949 - Topographical distribution of allelic loss in individual lung adenocarcinomas with lymp...
17083569 - Identification of dfna5 as a target of epigenetic inactivation in gastric cancer.
18241079 - The methylator phenotype in microsatellite stable colorectal cancers is characterized b...
23199579 - Pathological controversies in breast cancer: classification of ductal carcinoma in situ...
18307539 - Clinical features and mismatch repair genes analyses of chinese suspected hereditary no...
15752739 - Psychological stress induces chemoresistance in breast cancer by upregulating mdr1.
19005969 - Mediterranean diet and breast density in the minnesota breast cancer family study.
15703619 - Colorectal cancer in inflammatory bowel disease.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2008-04-11
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  114     ISSN:  1573-7217     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-02-04     Completed Date:  2009-04-07     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  315-25     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / genetics*,  pathology,  therapy
Carcinoma, Ductal, Breast / genetics,  secondary,  therapy
Carcinoma, Lobular / genetics,  secondary,  therapy
DNA Methylation*
Lymphatic Metastasis
Middle Aged
Neoplasm Recurrence, Local / genetics*,  pathology,  therapy
Polymerase Chain Reaction
Promoter Regions, Genetic / genetics*
Prospective Studies
Sentinel Lymph Node Biopsy*
Survival Rate
Tumor Markers, Biological / genetics*
Tumor Suppressor Proteins / genetics
Grant Support
CA88843/CA/NCI NIH HHS; L30 CA111124/CA/NCI NIH HHS; L30 CA111124-01/CA/NCI NIH HHS; P50 CA088843/CA/NCI NIH HHS; P50 CA088843-04/CA/NCI NIH HHS; P50 CA088843-06A19005/CA/NCI NIH HHS
Reg. No./Substance:
0/Tumor Markers, Biological; 0/Tumor Suppressor Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morpho...
Next Document:  Transcriptional profiles of progestogen effects in the postmenopausal breast.